85 results about "Spinal Nerve Disorders" patented technology

The present disclosure describes methods of administering N-acetylcysteine (NAC) via intranasal nose-to-brain administration. The effect of intranasal NAC nose-to-brain administration can be monitored using an analytical technique, for example, magnetic resonance spectroscopy (MRS). In some embodiments, intranasal nose-to-brain NAC can be used to treat a condition, for example, a brain injury.

A method for delivering a therapeutic agent to a human brain by delivering systemically a therapeutic agent and applying low intensity pulsed ultrasound (“LIPU”) to the brain in the presence of circulating microbubbles. The therapeutic agent is delivered prior to applying LIPU if it has a plasma half-life of ≥1 h, and the therapeutic agent is delivered after applying LIPU if it has a plasma half-life of <1 h. In a second disclosed method, a first therapeutic agent is delivered systemically, LIPU is applied to the brain in the presence of circulating microbubbles, and a second therapeutic agent is delivered systemically. Also provided is a method for treating a brain disorder in a human by delivering a therapeutic agent systemically, administering a microbubble solution, and applying LIPU to the brain for a period of 1 min. to 30 min.

Provided herein are tetracyclic heterocyclic compounds which can be useful for methods of treating a disease or for increasing neural plasticity. The compounds can also be useful for increasing dendritic spine density.

Provided herein are tetracyclic heterocyclic compounds which can be useful for methods of treating a disease or for increasing neural plasticity. The compounds can also be useful for increasing dendritic spine density.

The invention relates to a compound according to general formula (I), which acts as a bradykinin (BK) B2 receptor antagonist; to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to said compound(s) for use as in a method of treating a skin disorder; eye disease; ear disease; mouth, throat and respiratory disease; gastrointestinal disease; liver, gallbladder and pancreatic disease; urinary tract and kidney disease; disease of male genitale organs and female genitale organs; disease of the hormone system; metabolic disease; cardiovascular disease; blood disease; lymphatic disease; disorder of the central nervous system; brain disorder; musculoskeletal system disease; allergy disorder; pain; infectious disease; inflammatory disorder; injury; immunology disorder; cancer; hereditary disease; or edema.

Disclosed are a method and an apparatus for classifying patients with brain disorders based on EEG analysis. The method for classifying patients with brain disorders based on EEG analysis includes: (a) receiving an EEG data set with a clinical diagnosis label, wherein the EEG data set includes a plurality of EEG signals and age information; (b) augmenting the EEG data set through a deep learning-based screening model, and augmenting the EEG signals and the age information in different schemes; (c) training the deep learning-based screening model to classify EEG data of patients into a target clinical diagnosis label by using the augmented EEG signals and age information; and (d) predicting a brain diagnosis label of brain disorders by applying EEG data of patients to the trained deep learning-based screening model.

Targeted and individualized methods are provided herein for determining specific treatment sites based on an individual patient. Embodiments described herein may use functional and / or structural connections to create brain mapping of the patient and / or control groups having the same metrics as the patient, and combinations thereof in determining target locations for stimulation treatment.

The invention relates to a compound according to general formula (I), which acts as a bradykinin (BK) B2 receptor antagonist; to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to said compound(s) for use as in a method of treating a skin disorder; eye disease; ear disease; mouth, throat and respiratory disease; gastrointestinal disease; liver, gallbladder and pancreatic disease; urinary tract and kidney disease; disease of male genitale organs and female genitale organs; disease of the hormone system; metabolic disease; cardiovascular disease; blood disease; lymphatic disease; disorder of the central nervous system; brain disorder; musculoskeletal system disease; allergy disorder; pain; infectious disease; inflammatory disorder; injury; immunology disorder; cancer; hereditary disease; or edema.

Disclosed are a method and an apparatus for classifying patients with brain disorders based on EEG analysis. The method for classifying patients with brain disorders based on EEG analysis includes: (a) receiving an EEG data set with a clinical diagnosis label, wherein the EEG data set includes a plurality of EEG signals and age information; (b) augmenting the EEG data set through a deep learning-based screening model, and augmenting the EEG signals and the age information in different schemes; (c) training the deep learning-based screening model to classify EEG data of patients into a target clinical diagnosis label by using the augmented EEG signals and age information; and (d) predicting a brain diagnosis label of brain disorders by applying EEG data of patients to the trained deep learning-based screening model.

The present invention provides R-3,4-methylenedioxy-N,N-dimethylamphetamine, and salts thereof, for treating brain disorders.

The present invention relates to a method for making a non-human primate model of cerebral infarction comprising a step of administering endothelin to the brain basal nucleus-thalamic region of a non-human primate, thereby inducing brain basal nucleus disorders, thalamic disorders and endocystic disorders, and a method for treating subacute stages-containing NeuroD1 protein or a polynucleotide encoding a NeuroD1 protein The pharmaceutical composition can be used for treating chronic cerebral infarction, transbronchial infarction or cerebral infarction with brain disorder in a transbronchial dominating region.

Provided herein are tropane compounds which can be useful for methods of treating a disease or for increasing neural plasticity. The compounds can also be useful for increasing dendritic spine density.

Targeted and individualized methods are provided herein for determining specific treatment sites based on an individual patient. Embodiments described herein may use functional and / or structural connections to create brain mapping of the patient and / or control groups having the same metrics as the patient, and combinations thereof in determining target locations for stimulation treatment.

Disclosed are methods for quantification of a perivascular space in a subject's central nervous system. The methods include administering contrast agent into cerebrospinal fluid of the subject; performing quantitative ultra-short time-to-echo contrast-enhanced magnetic resonance imaging (QUTE-CE MRI) on a region of interest of the subject's brain; and determining presence of the contrast agent in the perivascular space within the region of interest.

A plurality of circular RNAs (circRNAs) the expression of which is correlated with brain disorders. The circRNAs are useful for compositions, kits, assays, and methods for the identification, diagnosis, screening, treatment and / or monitoring of brain disorders including psychiatric disorders such as bipolar disorder (BD), schizophrenia (SCZ), depression, Attention-Deficit / Hyperactivity Disorder (ADHD), Obsessive-compulsive disorder (OCD), Anxiety Disorders, etc., and neurodevelopmental disorders such as Autism, Asperger's Syndrome, and other Autism Spectrum Disorders (ASD), pervasive developmental disorders not otherwise specified (PDD-NOS), etc.

This invention discloses an essential oil-based intervention system for the simultaneous treatment of heart and brain function based on dual feedback of eye movement and heart rate variability, belonging to the field of rehabilitation medicine technology. The system includes: a data synchronization acquisition module, which acquires heart rate variability data and eye movement characteristic data and generates a synchronized physiological data stream; a dual feedback joint assessment module, which assesses the patient's real-time physical and mental state level based on the synchronized physiological data stream; a synchronized intervention decision module, which generates essential oil atomization control instructions and eye movement training control instructions in parallel according to the physical and mental state level; and a synchronized intervention execution module, which drives the essential oil atomization unit and the eye movement training unit to execute corresponding intervention actions synchronously at the hardware level on the time axis. This invention achieves integrated and precise intervention of heart and brain function through dual-modal physiological feedback closed loop and synchronized control, effectively solving the problems of brain separation, delayed intervention, and poor coordination in traditional rehabilitation centers, and improving the synchronous rehabilitation effect of cognitive function and autonomic nervous function in stroke patients.

Among the various aspects of the present disclosure is the provision of systems and methods of use for identifying brain disorders and pathological neurometabolic aging based on the frequency-based analysis of functional MRI imaging data.

Disclosed are compounds of formula (I) wherein G1 is as antagonists of the muscarinic acetylcholine receptor M4 (mAChR M4) for use in the treatment of e.g. a neurodegenerative disorder, a movement disorder, or a brain disorder, such as e.g. Parkinson's disease, drug-induced Parkinsonism, dystonia, Tourette's syndrome, dyskinesias, schizophrenia, cognitive deficits associated with schizophrenia, excessive daytime sleepiness, attention deficit hyperactivity disorder (ADHD), Huntington's disease, chorea, cerebral palsy, and progressive supranuclear palsy. An exemplary compound is e.g. (2,5-difluoro-4-(6-(((3aR,5s,6aS)-2-((tetrahydro-2H-pyran-4-yl)methyl)octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)phenyl)(imino)(methyl)-λ6-sulfanone (e.g. example 12; compound no. 7) Pharmacological data on the activity of the compounds in an mAChR M4 cell-based assay are provided (e.g. table 2).TABLE 2Human M4Cpd. No.IC50 (nM)Emin (%)*113.44239.62318.5345846575.4361883746.0385607918.43101.821186.231243.42138.63*% ACh maximum at 30 μM.

Methods of treatment and treatment systems for performing radiomodulatory stereotactic radiosurgery to treat brain disorders in which target neural tissues associated with the brain disorder are sensitized to radiation by administration of a molecular substance and / or non-targeted critical structures are protected from radiation by a molecular substance, in order to treat disorders of brain circuitry. Specific embodiments disclose means for treating pain, obesity and drug addiction.

Disclosed are compounds of Formula I that are useful as Monoacylglycerol lipase (MAGL) inhibitorsThese compounds may be used in pharmaceutical compositions, formulations, and methods for the treatment of disease states, disorders, and conditions benefited by the inhibition or modulation of MAGL activity, such as, but are not limited to, anxiety and mood disorder, metabolic disorder, a neurodegenerative disorder, mental disorder, brain disorder, pain, inflammatory disorder, cancer, Alzheimer's disease, movement disorders, epilepsy or stroke.

The application relates to the technical field of brain detection, and particularly discloses a test auxiliary system and method for brain diseases, wherein the system comprises an automatic control module, a light source control module and a data synchronization module. The automatic control module is used for inputting an open-closed eye test rule, converting the open-closed eye test rule into a light period control rule, and generating an open or off light instruction according to the light period control rule. The light source control module is used for controlling the switch state of an access light source according to the open or off light instruction, so as to simulate an open eye state and a closed eye state. The data synchronization module is used for acquiring environment brightness data and light source switch state data, and is also used for acquiring an electroencephalogram from an electroencephalogram test device and generating a visual report of the open-closed eye test. The technical scheme of the application can effectively solve the problem that a patient with a brain problem found in a nuclear magnetic resonance examination does not cooperate in an open-closed eye test, and improve test accuracy.

The present disclosure provides an AI-based clinical decision support system comprising an input module configured to receive clinical information comprising brain scan data, an analysis module configured to parse the clinical information using statistical measures from functional connectivity analysis with counterfactual explanations to identify brain connectivity patterns associated with brain disorders, and an output module configured to present a recommended diagnosis and explanation comprising attribution information identifying connectivity features contributing to the diagnosis. The brain scan data comprises functional magnetic resonance imaging, electroencephalography, and magnetoencephalography data. The statistical measures comprise functional connectivity analysis and graph theory metrics including degree metrics, betweenness centrality measures, and clustering coefficients. The analysis module comprises a functional connectivity engine configured to process brain scan data and generate connectivity features, a feature bank configured to store connectivity features, and modeling backbones configured to analyze connectivity features using machine learning techniques.

Among the various aspects of the present disclosure is the provision of systems and methods of use for identifying brain disorders and pathological neurometabolic aging based on the frequency-based analysis of functional MRI imaging data.

Compositions which treat lysosomal deficits in lysosomal storage disorders, neuronal ceroid lipofuscinosis, idiopathic / sporadic brain disorders that include neurological and psychiatric disorders, include agents such as troglitazone, rosuvastatin, Compound A or the combination thereof.

The present invention describes a method for the therapeutic treatment and / or for the diagnosis of a brain disorder including but not limited to cognitive disorders such as mild cognitive impairment, Alzheimer disease, frontotemporal dementia, dementia with Lowy body in a subject at risk of having or developing a brain disorder such as cognitive disorder, using long non-coding RNA (lncRNA).

A method of generating a population of cells useful for treating a brain disorder in a subject is disclosed. This disclosure provides compositions and methods to modify miR-155 in pluripotent cells, to differentiate the engineered pluripotent cells to disproportionately yield 155-3p or 155-5p in DA neurons and engraft the miR-155-3p or miR-155-5p biased DA neuron progenitors, astrocytic progenitors and / or leptomeningeal progenitors in a human subject to produce an anti-inflammatory effect.

Provided herein are compounds that function as modulators of the kinase DYRK1A and serotonin 2C receptor (5-HT2CR).